- Home
- COSM vs APRE Comparison
COSM vs APRE Comparison
Compare COSM & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- APRE
- Stock Information
- Founded
- COSM 2009
- APRE 2006
- Country
- COSM United States
- APRE United States
- Employees
- COSM N/A
- APRE N/A
- Industry
- COSM Other Pharmaceuticals
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COSM Health Care
- APRE Health Care
- Exchange
- COSM Nasdaq
- APRE Nasdaq
- Market Cap
- COSM 8.2M
- APRE 9.7M
- IPO Year
- COSM 2013
- APRE 2019
- Fundamental
- Price
- COSM $0.48
- APRE $1.75
- Analyst Decision
- COSM
- APRE Strong Buy
- Analyst Count
- COSM 0
- APRE 2
- Target Price
- COSM N/A
- APRE $15.50
- AVG Volume (30 Days)
- COSM 356.0K
- APRE 35.7K
- Earning Date
- COSM 05-15-2025
- APRE 05-14-2025
- Dividend Yield
- COSM N/A
- APRE N/A
- EPS Growth
- COSM N/A
- APRE N/A
- EPS
- COSM N/A
- APRE N/A
- Revenue
- COSM $53,554,457.00
- APRE $1,284,475.00
- Revenue This Year
- COSM $28.14
- APRE N/A
- Revenue Next Year
- COSM N/A
- APRE N/A
- P/E Ratio
- COSM N/A
- APRE N/A
- Revenue Growth
- COSM N/A
- APRE 33.27
- 52 Week Low
- COSM $0.28
- APRE $1.41
- 52 Week High
- COSM $1.58
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- COSM 57.76
- APRE 49.51
- Support Level
- COSM $0.44
- APRE $1.60
- Resistance Level
- COSM $0.50
- APRE $2.00
- Average True Range (ATR)
- COSM 0.04
- APRE 0.16
- MACD
- COSM 0.00
- APRE 0.02
- Stochastic Oscillator
- COSM 75.00
- APRE 37.50
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.